Top Page
Kontafarma China Holdings Ltd
(1312)
Kontafarma China Holdings Ltd (1312) vs. iShares MSCI Hong Kong ETF (EWH)
Kontafarma China Holdings Ltd Business Overview & Revenue Model
Kontafarma China Holdings Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 891.73M | 897.52M | 809.11M | 894.06M | 803.27M | 1.01B |
| Gross Profit | 493.63M | 516.16M | 471.29M | 506.22M | 396.18M | 555.75M |
| EBITDA | -79.14M | -49.93M | 78.50M | 26.93M | 112.18M | 156.31M |
| Net Income | -362.77M | -75.54M | -28.84M | -41.55M | -15.05M | -267.16M |
Balance Sheet | ||||||
| Total Assets | 1.15B | 1.59B | 1.73B | 2.12B | 2.56B | 2.54B |
| Cash, Cash Equivalents and Short-Term Investments | 78.33M | 90.58M | 87.66M | 142.59M | 183.96M | 194.79M |
| Total Debt | 235.86M | 297.19M | 333.82M | 590.72M | 728.95M | 782.61M |
| Total Liabilities | 532.12M | 625.90M | 665.39M | 964.16M | 1.22B | 1.19B |
| Stockholders Equity | 684.99M | 978.70M | 1.06B | 1.10B | 1.19B | 1.21B |
Cash Flow | ||||||
| Free Cash Flow | 32.13M | 33.41M | 12.92M | -53.84M | -49.31M | 51.02M |
| Operating Cash Flow | 49.63M | 47.05M | 37.12M | -2.17M | 75.07M | 206.93M |
| Investing Cash Flow | 6.74M | -6.01M | 144.14M | 121.53M | 23.24M | -206.12M |
| Financing Cash Flow | -35.78M | -42.52M | -198.81M | -137.33M | -99.80M | 19.10M |
Kontafarma China Holdings Ltd Technical Analysis
Kontafarma China Holdings Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | HK$226.95M | -0.71 | -32.04% | ― | -11.89% | -290.48% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$595.53M | -3.08 | -40.38% | ― | -43.46% | -96.48% | |
48 Neutral | HK$573.11M | -3.33 | ― | ― | ― | ― | |
48 Neutral | HK$211.34M | -40.20 | -8.71% | ― | 2.54% | 33.33% | |
46 Neutral | HK$167.36M | -0.48 | -41.48% | ― | 6.55% | -475.22% | |
41 Neutral | HK$184.55M | -3.69 | -33.22% | ― | -17.32% | 55.74% |
Kontafarma China Holdings Ltd Corporate Events
Kontafarma China Holdings Ltd has formalised updated terms of reference for its Audit Committee, stipulating that it must comprise at least three non-executive directors, with a majority being independent non-executive directors and at least one member possessing appropriate professional or accounting and financial management expertise as required under Hong Kong Listing Rules. The document strengthens the committee’s authority and procedures by setting minimum meeting frequency, quorum requirements, the ability to hold private sessions with internal and external auditors, and explicit powers to seek information from management, report suspected frauds, control failures or regulatory breaches to the board, and obtain independent professional advice at the company’s expense, underscoring a tighter governance and risk oversight framework for stakeholders.
The most recent analyst rating on (HK:1312) stock is a Hold with a HK$0.03 price target. To see the full list of analyst forecasts on Kontafarma China Holdings Ltd stock, see the HK:1312 Stock Forecast page.
Kontafarma China Holdings Ltd has set out the formal terms of reference for its board remuneration committee, which is composed entirely of non-executive directors with a majority of independent non-executive directors and chaired by an independent director. The company secretary serves as committee secretary, and the committee is required to meet at least annually, with provisions for additional meetings and participation via teleconference. The new framework empowers the committee to recommend and oversee policies on remuneration structure and levels for directors and senior management, including salaries, benefits, pensions and termination compensation, with reference to corporate objectives, peer company pay and internal conditions across the group. By codifying these responsibilities and procedures, Kontafarma aims to ensure a formal, transparent and competitive remuneration regime that helps attract and retain leadership while avoiding excessive pay, bolstering its corporate governance standards for stakeholders.
The most recent analyst rating on (HK:1312) stock is a Hold with a HK$0.03 price target. To see the full list of analyst forecasts on Kontafarma China Holdings Ltd stock, see the HK:1312 Stock Forecast page.
Kontafarma China Holdings Ltd has announced a change in the shareholding structure of its controlling shareholder. The People’s Government of Shanxi Province has decided to transfer significant equity interests in Shanxi Construction Investment Group Co., Ltd. and Shanxi Transportation Holdings Group Co., Ltd. from Shanxi State-owned Capital Operation Co., Ltd. to the Shanxi Government Commission. This transfer does not alter the direct controlling shareholder of Kontafarma, which remains Waranty Assets Management (HK) Limited, nor does it change the ultimate beneficial ownership by the Shanxi Government Commission. The transfer is pending the completion of business registration changes.
The most recent analyst rating on (HK:1312) stock is a Hold with a HK$0.03 price target. To see the full list of analyst forecasts on Kontafarma China Holdings Ltd stock, see the HK:1312 Stock Forecast page.
Kontafarma China Holdings Limited announced the resignation of Ms. Qiao Linna from her roles as an executive director and vice president, effective November 14, 2025. Ms. Qiao’s departure also results in her cessation as a member of the company’s executive and share dealing committees. The board expressed gratitude for her contributions and confirmed there are no disagreements or issues requiring shareholder attention.
Kontafarma China Holdings Ltd has announced a restructuring of its board of directors, effective November 14, 2025. The company has appointed Wang Feifei as Chairman and President, with Guo Zixiu as Financial Controller, and Liu Jiankun as an Executive Director. The board also includes a Non-Executive Director and three Independent Non-Executive Directors. This restructuring is likely to impact the company’s governance and strategic direction, potentially influencing its market position and stakeholder confidence.
Kontafarma China Holdings Ltd announced that its adjourned extraordinary general meeting successfully passed all proposed resolutions, including the approval of a significant construction contract for a research and development complex in Beijing. This contract, valued at over RMB33 million, is expected to enhance the company’s R&D capabilities, potentially strengthening its market position and benefiting stakeholders.
Kontafarma China Holdings Ltd has announced the adjournment of its Extraordinary General Meeting (EGM) initially scheduled for October 20, 2025, to November 7, 2025, due to the need for additional preparation time. The venue remains unchanged, and the period for determining shareholder entitlements to attend and vote also remains the same. Shareholders who have already submitted proxy forms do not need to resubmit them, as they remain valid for the adjourned meeting.